August 27, 2014—Drug manufacturers are free to challenge the new 340B orphan drug exclusion “interpretative” rule, but they cannot do so as part of their successful lawsuit against the orphan drug “legislative” rule that came before, a federal district judge ruled this morning.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register.
Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)